Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Arzneiwerk VIDA Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Sascha Knoche

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Sascha Knoche

less than a year

Görev süresi

Sascha Knoche is CEO & Chairman of the Management Board of Arzneiwerk AG VIDA (formerly known as TELES Aktiengesellschaft) from January 01, 2024.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joachim Schwarzer	Chairman of the Supervisory Board	8yrs	€50.00k	Veri yok
Hartmut Brandt	Member of Supervisory Board	5.2yrs	€20.00k	Veri yok
Markus Schmieta	Deputy Chairman of the Supervisory Board	5.2yrs	€30.00k	Veri yok

5.2yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: TLIK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).

Arzneiwerk VIDA Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

TELES AG Informationstechnologien, Annual General Meeting, Jul 28, 2023

TELES Aktiengesellschaft Informationstechnologien, Annual General Meeting, May 28, 2021

Recent updates

First quarter 2024 earnings released: €0.036 loss per share (vs €0.064 loss in 1Q 2023)

New minor risk - Share price stability

Full year 2023 earnings released: €0.46 loss per share (vs €0.27 loss in FY 2022)

New major risk - Share price stability

TELES Aktiengesellschaft to Report Q1, 2024 Results on May 27, 2024

Third quarter 2022 earnings released: €0.058 loss per share (vs €0.045 loss in 3Q 2021)

Third quarter 2022 earnings released: €0.038 loss per share (vs €0.045 loss in 3Q 2021)

New major risk - Market cap size

TELES AG Informationstechnologien to Report Fiscal Year 2022 Results on Aug 25, 2023

TELES AG Informationstechnologien to Report Fiscal Year 2022 Results on Jul 14, 2023

TELES AG Informationstechnologien, Annual General Meeting, Jul 28, 2023

TELES AG Informationstechnologien to Report First Half, 2023 Results on Aug 07, 2023

Second quarter 2022 earnings released: €0.037 loss per share (vs €0.001 profit in 2Q 2021)

Now 23% undervalued

Full year 2021 earnings: Revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

TELES AG Informationstechnologien (XTRA:TLIK) acquired unknown majority stake in EURO RX Arzneimittel GmbH.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released

Investor sentiment improved over the past week

TELES AG Announces Earnings Guidance for the Year 2021

First quarter 2021 earnings released

Investor sentiment deteriorated over the past week

TELES AG Provides Earnings Guidance for the Year 2020

Investor sentiment improved over the past week

TELES Aktiengesellschaft Informationstechnologien, Annual General Meeting, May 28, 2021

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Market pulls back on stock over the past week

Market bids up stock over the past week

Third quarter earnings released

New 90-day high: €1.55

New 90-day low: €1.04

New 90-day low - €1.21

TELES Aktiengesellschaft Informationstechnologien has completed a Follow-on Equity Offering in the amount of €1.514804 million.

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi